Stage IIIB Skin Melanoma Active Not Recruiting Phase 2 Trials for Aldesleukin (DB00041)

IndicationStatusPhase
DBCOND0029534 (Stage IIIB Skin Melanoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02748564Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTreatment